Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PVAIN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Alpha-CLDN-VC0101
|
|||||
| Synonyms |
CLDN18.2-ADC (Pfizer); CLDN18.2 ADC (Pfizer)
Click to Show/Hide
|
|||||
| Organization |
Pfizer Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Clinical candidate
Pancreatic cancer [ICD11:2C10]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Auristatin 0101
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugated of maleimidocaproyl with cysteine free thiol via Michael addition.
|
|||||
| Combination Type |
Pelidotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.